psq.p

P Squared Renewables Inc. Announces Change of Name to Universal Ibogaine Inc.

(TheNewswire)



September 17, 2021 TheNewswire - Calgary, Alberta - P Squared Renewables Inc. (TSXV:PSQ.P) (" PSQ ") announces that as part of the completion of its recently announced Qualifying Transaction (the " QT ", as such term is defined under Policy 2.3 of the Corporate Finance Manual of the TSX Venture Exchange) it has formally changed its name to Universal Ibogaine Inc.

As noted in PSQ's news release of September 2, 2021, the QT involved a three cornered Amalgamation among PSQ, 1266855 B.C. Ltd. (" Subco ", a wholly owned subsidiary of PSQ), and Universal Ibogaine Inc. (" UI ").

The continuing entity (the " Resulting Issuer ") has now completed a formal name change to "Universal Ibogaine Inc." while UI and Subco Amalgamated on August 31, 2021 and continue as a B.C. corporation which was renamed "Clear Sky Recovery Solutions Inc.", which is a wholly owned subsidiary of UI.

Final TSXV Approval and Resumption of Trading

The ultimate listing of the common shares of the Resulting Issuer UI is subject to final approval by the TSXV, and resumption of trading of the common shares (under the intended trading symbol "IBO") is subject to TSXV conditions which UI is in process of completing, prior to the expected issuance in the coming weeks of the ultimate Final Exchange Bulletin by the TSXV.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

‎This news release contains forward-looking statements and information. More particularly, this ‎document contains statements and information relating to the QT that remains subject to final submissions and approval from the TSXV, as well as the intended name change . Forward-looking information is frequently characterized by words such ‎as "plan", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI, including expectations and assumptions concerning timing of ‎receipt of required regulatory approval and the satisfaction of other conditions to the completion of ‎ the QT. Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

‎‎ For further information regarding the Transaction, please contact:

Rami Batal        Shabir Premji

Chief Executive Officer        Former Executive Chairman & CEO

Universal Ibogaine Inc.        P Squared Renewables Inc.

Telephone: 416-902-4090        Telephone: 403-870-1841

Email: Rami.Batal@universalibogaine.com        Email: spremji@p2renewables.com

NOT FOR DISSEMINATION IN THE UNITED STATES
OR THROUGH U.S. NEWS WIRES

Copyright (c) 2021 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)
Invion Limited

Invion Doses First Patient in Phase I/II Non-Melanoma Skin Cancer Trial

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce the dosing of the first patient in its Phase I/II non- melanoma skin cancer (NMSC) trial conducted at Veracity Clinical Research (Veracity) in Brisbane.

Keep reading...Show less
BPH Global

Seaweed Extraction of Critical Minerals R&D

BPH Global (BP8:AU) has announced Seaweed Extraction of Critical Minerals R&D

Download the PDF here.

Resonance Health Ltd

Resonance Contracted by Major Global Pharma Company for Clinical Drug Trial Worth $13.775 Million over 24 Months

Resonance Health Ltd (ASX: RHT) (Resonance or the Company) advises that it has been contracted by Sun Pharmaceutical Industries Limited, an international, publicly listed pharmaceutical company with global operations (Customer) to be the local Australian sponsor, and to provide clinical research organisation (CRO) services, trial site services, and imaging analysis services (collectively, Services), for their clinical trial in Australia of a new drug compound (Clinical Trial).

Keep reading...Show less
  Island Pharmaceuticals

ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update

Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever.

Keep reading...Show less

Latest Press Releases

Related News

×